CoChat

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

Open access
Buss, Lewis F., Prete, Carlos A., Abrahim, Claudia M. M., Mendrone, Alfredo, Salomon, Tassila, de Almeida-Neto, Cesar, França, Rafael F. O., Belotti, Maria C., Carvalho, Maria P. S. S., Costa, Allyson G., Crispim, Myuki A. E., Ferreira, Suzete C., Fraiji, Nelson A., Gurzenda, Susie, Whittaker, Charles, Kamaura, Leonardo T., Takecian, Pedro L., da Silva Peixoto, Pedro, Oikawa, Marcio K., Nishiya, Anna S., Rocha, Vanderson, Salles, Nanci A., de Souza Santos, Andreza Aruska, da Silva, Martirene A., Custer, Brian, Parag, Kris V., Barral-Netto, Manoel, Kraemer, Moritz U. G., Pereira, Rafael H. M., Pybus, Oliver G., Busch, Michael P., Castro, Márcia C., Dye, Christopher, Nascimento, Vítor H., Faria, Nuno R., Sabino, Ester C. · 2021 · Science

Published version of a preprint

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.abe9728

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Abbott SARS-CoV-2 N IgG chemiluminescence assay performance and antibody dynamics in different clinical samples. (A) Signal-to-cutoff (S/C) values using the Abbott chemiluminescence assay (CMIA) in the following clinical samples (from left to right): 821 routine blood donation samples from Manaus in February 2020, >1 month before the first notified case in the city; 49 samples collected at 20 to 33 days after symptom onset from SARS-CoV-2 PCR-positive patients in São Paulo requiring hospital care; 193 patients in São Paulo with PCR-confirmed symptomatic COVID-19 not requiring hospital care, with plasma donation samples taken in the early convalescent period; 107 samples from the same nonhospitalized plasma donor cohort from the late convalescent period; 133 samples that tested positive on either the Abbott CMIA or the Roche Elecsys assay out of 1000 routine blood donations collected in July 2020 and tested in parallel from the Fundação Pró-Sangue blood center (São Paulo). Upper dashed line denotes the manufacturer’s threshold for positive result of 1.4 S/C; lower dashed line denotes an alternative threshold of 0.4 S/C. In the box plots of Abbott IgG CMIA S/C, the central line is the median; upper and lower hinges are the 25th and 75th centiles, respectively; whiskers show the range, extending to a maximum of 1.5 times the interquartile range from the hinge. (B) S/C values of the Abbott CMIA for 104 convalescent plasma donors who were sampled at two different times. (C) Histogram of the slopes among 88 individuals shown in (B) who tested positive (>1.4 S/C) at the first time point. POS, post–onset of symptoms.
Fig. 1 Abbott SARS-CoV-2 N IgG chemiluminescence assay performance and antibody dynamics in different clinical samples. (A) Signal-to-cutoff (S/C) values using the Abbott chemiluminescence assay (CMIA) in the following clinical samples (from left to right): 821 routine blood donation samples from Manaus in February 2020, >1 month before the first notified case in the city; 49 samples collected at 20 to 33 days after symptom onset from SARS-CoV-2 PCR-positive patients in São Paulo requiring hospital care; 193 patients in São Paulo with PCR-confirmed symptomatic COVID-19 not requiring hospital care, with plasma donation samples taken in the early convalescent period; 107 samples from the same nonhospitalized plasma donor cohort from the late convalescent period; 133 samples that tested positive on either the Abbott CMIA or the Roche Elecsys assay out of 1000 routine blood donations collected in July 2020 and tested in parallel from the Fundação Pró-Sangue blood center (São Paulo). Upper dashed line denotes the manufacturer’s threshold for positive result of 1.4 S/C; lower dashed line denotes an alternative threshold of 0.4 S/C. In the box plots of Abbott IgG CMIA S/C, the central line is the median; upper and lower hinges are the 25th and 75th centiles, respectively; whiskers show the range, extending to a maximum of 1.5 times the interquartile range from the hinge. (B) S/C values of the Abbott CMIA for 104 convalescent plasma donors who were sampled at two different times. (C) Histogram of the slopes among 88 individuals shown in (B) who tested positive (>1.4 S/C) at the first time point. POS, post–onset of symptoms.CC BY · PubMed Central
Fig. 2 Monthly antibody prevalence and signal-to-cutoff (S/C) reading in Manaus and São Paulo. (A and C) SARS-CoV-2 antibody prevalence estimates in Manaus (A) and São Paulo (C) with a range of corrections, from left to right: reweighting positive tests, at positivity threshold of 1.4 S/C, to the age and sex distribution of each city; further correcting for sensitivity and specificity at this assay threshold; reweighting positive tests for age and sex at a reduced threshold of 0.4 S/C; correcting for sensitivity and specificity at this threshold; and finally correcting for seroreversion. Error bars are 95% confidence intervals. Gray bars are standardized daily mortality using confirmed COVID-19 deaths from the SIVEP-Gripe (Sistema de Informação de Vigilância Epidemiológica da Gripe; https://covid.saude.gov.br/) notification system and standardized by the direct method using the total projected Brazilian population for 2020 as reference. Black lines are rescaled cumulative deaths, such that the maximum is set to the maximum seroprevalence estimate for each city. Mortality data are plotted according to the date of death. (B and D) Distribution of S/C values over the nine monthly samples are shown for Manaus (B) and São Paulo (D). Each point represents the S/C reading for a single donation sample. Upper dashed line denotes the manufacturer’s threshold (1.4 S/C units); lower dashed line denotes an alternative threshold (0.4 S/C units); black box plots show the median (central lines), interquartile range (hinges), and range extending to 1.5 times the interquartile range from each hinge (whiskers) of S/C values above 0.4 (i.e., excluding very low and likely true-negative values).
Fig. 2 Monthly antibody prevalence and signal-to-cutoff (S/C) reading in Manaus and São Paulo. (A and C) SARS-CoV-2 antibody prevalence estimates in Manaus (A) and São Paulo (C) with a range of corrections, from left to right: reweighting positive tests, at positivity threshold of 1.4 S/C, to the age and sex distribution of each city; further correcting for sensitivity and specificity at this assay threshold; reweighting positive tests for age and sex at a reduced threshold of 0.4 S/C; correcting for sensitivity and specificity at this threshold; and finally correcting for seroreversion. Error bars are 95% confidence intervals. Gray bars are standardized daily mortality using confirmed COVID-19 deaths from the SIVEP-Gripe (Sistema de Informação de Vigilância Epidemiológica da Gripe; https://covid.saude.gov.br/) notification system and standardized by the direct method using the total projected Brazilian population for 2020 as reference. Black lines are rescaled cumulative deaths, such that the maximum is set to the maximum seroprevalence estimate for each city. Mortality data are plotted according to the date of death. (B and D) Distribution of S/C values over the nine monthly samples are shown for Manaus (B) and São Paulo (D). Each point represents the S/C reading for a single donation sample. Upper dashed line denotes the manufacturer’s threshold (1.4 S/C units); lower dashed line denotes an alternative threshold (0.4 S/C units); black box plots show the median (central lines), interquartile range (hinges), and range extending to 1.5 times the interquartile range from each hinge (whiskers) of S/C values above 0.4 (i.e., excluding very low and likely true-negative values).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1186/1742-7622-9-9 · DOI

Cited by

See all 488

Metadata

Authors
Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., Crispim, M. A. E., Ferreira, S. C., Fraiji, N. A., Gurzenda, S., Whittaker, C., Kamaura, L. T., Takecian, P. L., da Silva Peixoto, P., Oikawa, M. K., Nishiya, A. S., Rocha, V., Salles, N. A., de Souza Santos, A. A., da Silva, M. A., Custer, B., Parag, K. V., Barral-Netto, M., Kraemer, M. U. G., Pereira, R. H. M., Pybus, O. G., Busch, M. P., Castro, M. C., Dye, C., Nascimento, V. H., Faria, N. R., & Sabino, E. C.
Affiliations
  • Universidade de São Paulo (BR)
  • Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
  • Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (BR)
  • Faculdade de Ciências Médicas de Minas Gerais (BR)
  • Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil.
  • Department of Virology and Experimental Therapy, Institute Aggeu Magalhaes, Oswaldo Cruz Foundation, Recife, Brazil.
  • Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
  • Harvard University (US)
  • Imperial College London (GB)
  • Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
  • Center of Mathematics, Computing and Cognition–Universidade Federal do ABC, São Paulo, Brazil.
  • Fundação Pró-Sangue Hemocentro de São Paulo (BR)
  • Oxford School of Global and Area Studies, Latin American Centre, University of Oxford, Oxford, UK.
  • University of California, San Francisco (US)
  • Instituto Gonçalo Moniz–Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
  • University of Oxford (GB)
  • Institute of Applied Economic Research (BR)
  • Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Corresponding author
  • Buss, Lewis F.
  • Abrahim, Claudia M. M.
  • Mendrone, Alfredo
  • Salomon, Tassila
  • Faria, Nuno R.
Venue
Science
Published
2021-01-15
Volume
371
Issue
6526
Pages
288-292
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W3112547455
Cited by
488
References
47
Citations by year
2026: 10 · 2025: 17 · 2024: 29 · 2023: 56 · 2022: 119 · 2021: 240
FWCI
35.12
Type
journal article
Language
en
Open access
Locations
  • Science (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
Funders
  • Medical Research Council (MR/S0195/1)
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (18/14389-0)
  • Itau Unibanco Todos pela Saude
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
SARS-CoV-2, COVID-19 pandemic, attack rate, seroprevalence, immunoglobulin G antibodies, Manaus, Amazonas, antibody waning, blood donors, epidemic size estimation
MeSH terms
COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Antibodies, Viral, Blood Donors, Brazil, Female, Humans, Immunoglobulin G, Male, Middle Aged, Seroepidemiologic Studies, Young Adult, Epidemics, Epidemiological Monitoring

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.